Category: Uncategorized
-
Not launching in Europe is not the solution. European access preparedness – growing opportunities and risk mitigation
In today’s turbulent geopolitical dynamics, there are many more moving parts when it comes to pricing, reimbursement and market access. What are the key trends that come together, and what is the case for paying closer attention to European markets when there is considerable price & access pressure from the other side of the Atlantic?…
-
Biotech market access preparedness
In a world where pricing and access dynamics have just gotten more complex, the market potential of a health technology needs to be shaped early. Let’s take a look at the framework and key elements of market access preparedness.
-
What Investors Want You to Know About Regulatory and Market Access Strategies
You are invited! Eurofins Medical Device Services is organising this extremely relevant webinar with their regulatory and device development expertise. Apersy is pleased to join them with the Market Access and reimbursement point of view.
-
Starting 2025: Don’t forget to look beyond the JCA
While we are certainly all on lookout for the first EU Joint Clinical Assessments (JCA), there are quite a few other access, financing, pricing and reimbursement news and changes to watch as 2025 starts…
-
Exploring access and reimbursement of digital medical devices and AI-based SaMD at ISPOR Europe 2024
How to approach reimbursement and access of DMDs? DMD reimbursement remains a highly dynamic, where complex access options need to be carefully evaluated, followed and potentially re-evaluated. While access strategy needs to be tailored to each device, some general questions for the DMD field should be considered for each evidence generation plan and go-to-market plan:…
-
Weighing the Costs: Reimbursement of Anti-Obesity Medicines in the US and Europe
With the global burden of obesity continuing to rise, the tension between established reimbursement rules, increased efficacy of new anti-obesity medicines and the need to tackle this population health issue is becoming more pronounced. Reimbursement policies for anti-obesity medications vary significantly by region and are driven by country-specific healthcare priorities, reimbursement policies and budget constraints,…
-
Uncertainties Surrounding the EU Joint Clinical Assessment: What do biotechs need to monitor
With the implementation of the new EU Health Technology Assessment (HTA) Regulation just four months away, uncertainties remain. The most important ones we will look at in this short clip, before exploring strategies for success the next time.
-
Nononsense EU JCA
No-nonsense EU HTA Introducing bit-sized no-nonsense insights about the EU HTA Regulation, Joint Clinical Assessment, Joint Scientific Consultations, etc etc. In a series of posts, there will be Q&A, process overviews, insights about preparedness, uncertainties and unknowns, as well as news as they happen in the continuing implementation phase. Got a question or query to…
-
The dynamics in diagnostic imaging tenders and funding
Reimbursement, access, competition and purchasing are highly dynamic in the diagnostic imaging technology field.
-
Apersy’s 1st anniversary
I started with the vision to create independent market access services that can support health tech companies through the challenges of precision medicine, complex treatment regimens and care approaches that blur the boundaries between device, pharmaceuticals and digital.